This study examines the association between suicide and exposure to angiotensin receptor blockers and angiotensin-converting enzyme inhibitors.
Ontario Prescription Opioid Tool: Update July 2019
This tool allows public access to data related to indicators for opioid prescribing in the province. It has been updated to include data up to March 2019 (April 2019 for naloxone) and two new indicators to capture individuals newly dispensed a prescription opioid for pain or opioid agonist therapy.
This study evaluates the risk of cardiac arrhythmias and other cardiovascular adverse events in older adults receiving mirabegron prescribed to treat overactive bladder.
This report aims to advance understanding of the current rise of opioid-related deaths, as well as inform public health practice and system planning that addresses opioid-related harms in the province.